Innovative Paradigms for ART: Implementation Insights From an Expert Panel

Innovative Paradigms for ART: Implementation Insights From an Expert Panel (July 2019)

Sunday, July 21, 2019
Webinar -- 12:45 PM CT


  • Overview of Key Characteristics and Practical Considerations for Novel ART Paradigms
  • Panel Discussion: Key Questions on Oral 2-drug ART Regimens
  • Panel Discussion: Key Questions on Injectable Long-acting ART
  • Questions and Answers


Program Director
Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Andrea Mantsios, PhD

Research Fellow
Center for Health, Risk and Society
American University
Washington, DC

Anthony Mills, MD

President, Southern California Men's Medical Group
CEO and CMO, Men's Health Foundation
President & Clinical Research Director, Mills Clinical Research
Assistant Professor of Clinical Medicine
University of California, Los Angeles
Los Angeles, California

Omar Sued, MD, PhD

Director, Research Department
Fundación Huésped
Buenos Aires, Argentina

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Goal Statement
The goal of this activity is to improve participants’ knowledge and competence regarding the clinical role of innovative antiretroviral regimens.

Target Audience
This program is intended for physicians and other healthcare professionals who provide care for HIV-infected patients.

Learning Objectives

  • Incorporate innovate ART strategies into the management of persons with HIV infection based on key data and practice guidelines
  • Appraise 2-drug vs 3-drug treatment strategies in the care of persons with HIV infection
  • Devise strategies to incorporate the use of long-acting ART as a treatment option for appropriate candidates, once available


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.